Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 1/20 | 0.59 |
| ▸ | PDE1A | P54750 | 8/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.44 |
| ▸ | PDE2A | O00408 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PARG | Q86W56 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000713 | 0.80 | MAPT (0.47) | PDE1APDE1BPDE1CPDE2AMAPT | |
| SCHEMBL2456336 | 0.79 | MAPT (0.45) | PDE1APDE1BPDE1CPDE2AMAPT | |
| SCHEMBL2458632 | 0.78 | SLC16A1 (0.57) | SLC16A1PDE1APDE1BPDE1CPDE2A | |
| SCHEMBL2453873 | 0.78 | PDE1A (0.48) | SLC16A1PDE1APDE1BPDE1CPDE2A | |
| SCHEMBL2532754 | 0.77 | SLC16A1 (0.58) | SLC16A1PDE1APDE1BPDE1CPDE2A | |
| SCHEMBL7057783 | 0.74 | SLC16A1 (1.00) | SLC16A1PDE1APDE1BPDE1CPDE2A | |
| SCHEMBL2454552 | 0.72 | PDE1A (0.46) | SLC16A1PDE1APDE1BPDE1CPDE2A | |
| SCHEMBL2461370 | 0.72 | PDE1A (0.49) | SLC16A1PDE1APDE1BPDE1CPDE2A | |
| SCHEMBL3390646 | 0.71 | MAPT (0.47) | PDE1APDE1BPDE1CPDE2AMAPT | |
| SCHEMBL17644502 | 0.70 | MAPT (0.46) | PDE1APDE1BPDE1CPDE2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371327-B2 | PDE1 inhibitor compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2367428-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20150353556-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-12-10 | — | — | US | disclosed |
| US-8927556-B2 | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130324565-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| EP-2590657-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120136013-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES. INC. | 2012-05-31 | — | — | US | disclosed |
| WO-2011153135-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| WO-2010065147-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353556-A1 | ORGANIC COMPOUNDS | CYP2C9, TPMT, CYP2C19 | SLC16A1 3802/4885PDE1A 4874/4885PDE1B 4863/4885 |
| US-20120136013-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | SLC16A1 3816/4885PDE1A 4874/4885PDE1B 4855/4885 |
| US-20130324565-A1 | ORGANIC COMPOUNDS | UGT2B7, CYP2C9, CYP4B1 | SLC16A1 4363/4885PDE1A 4846/4885PDE1B 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.